CBX3 has been previously identified as a potential biomarker for tumor stem cells in osteosarcoma [59], while CBX4 has been reported to induce hypoxia-mediated activation of VEGFA (vascular endothelial growth factor A) and angiogenesis in hepatocellular carcinomas [60]. This evidence concerns the gene VEGFA and osteosarcoma.